Patients being treated with Yescarta for primary mediastinal B-cell lymphoma (PMBCL) may be at increased risk for developing cerebral edema, including fatal events, compared to other large B-cell lymphomas. Cerebral edema is a known risk of CAR T-cell therapy and is described in the Yescarta Canadian product monograph (CPM).
RecallTracker